IRIS
Fiorino, Gionata
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.085
EU - Europa 1.518
AS - Asia 865
AF - Africa 251
OC - Oceania 17
SA - Sud America 12
Continente sconosciuto - Info sul continente non disponibili 7
Totale 9.755
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.993
SG - Singapore 453
FI - Finlandia 409
IE - Irlanda 268
CN - Cina 238
NG - Nigeria 224
DE - Germania 152
FR - Francia 144
IT - Italia 120
SE - Svezia 96
GB - Regno Unito 95
NL - Olanda 92
CA - Canada 85
TR - Turchia 41
IL - Israele 38
IN - India 38
BE - Belgio 34
ES - Italia 21
RU - Federazione Russa 21
CZ - Repubblica Ceca 15
AU - Australia 14
EG - Egitto 12
IR - Iran 12
UA - Ucraina 12
DZ - Algeria 11
JP - Giappone 11
HK - Hong Kong 8
CL - Cile 7
RO - Romania 7
IQ - Iraq 6
MX - Messico 5
PT - Portogallo 5
VN - Vietnam 5
A2 - ???statistics.table.value.countryCode.A2??? 4
GR - Grecia 4
NO - Norvegia 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
BR - Brasile 3
EU - Europa 3
LT - Lituania 3
NZ - Nuova Zelanda 3
QA - Qatar 3
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BO - Bolivia 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
KZ - Kazakistan 2
MD - Moldavia 2
PK - Pakistan 2
PL - Polonia 2
BD - Bangladesh 1
BY - Bielorussia 1
DK - Danimarca 1
ET - Etiopia 1
KR - Corea 1
MT - Malta 1
MY - Malesia 1
PH - Filippine 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
ZA - Sudafrica 1
Totale 9.755
Salva come PNG Salva come JPEG
Città #
Wilmington 1.555
Chandler 1.248
San Mateo 589
Ann Arbor 437
Helsinki 409
Singapore 298
Leawood 287
Lawrence 273
Princeton 273
Dublin 263
Benin City 223
Boardman 213
Shanghai 180
Ashburn 170
Woodbridge 152
Fairfield 151
Paris 141
New York 140
Amsterdam 86
Toronto 73
London 56
Norwalk 47
Milan 41
Kocaeli 40
Seattle 40
Brussels 33
Monmouth Junction 28
San Diego 28
Phoenix 26
Redwood City 26
Pune 17
Abbiategrasso 16
Cambridge 16
Santa Clara 15
Beijing 14
Brno 13
Los Angeles 10
Houston 9
Collegeville 8
Moscow 8
Redmond 8
Warrington 8
Bury 7
Cairo 7
Des Moines 7
Duncan 7
Falkenstein 7
Munich 7
Rome 7
Sacramento 7
Baghdad 6
Frankfurt am Main 6
Gunzenhausen 6
Kemerovo 6
Valencia 6
Brisbane 5
Hong Kong 5
Kikunodai 5
St Louis 5
Zhengzhou 5
Andover 4
Clearwater 4
Delhi 4
Henderson 4
Lisbon 4
Ottawa 4
San Pedro 4
Tappahannock 4
Washington 4
Asyut 3
Cupertino 3
Doha 3
Glasgow 3
Hanoi 3
Hanover 3
Heerenveen 3
Hyderabad 3
Las Vegas 3
Oran 3
Osaka 3
Padova 3
Raleigh 3
Seville 3
Sydney 3
Zanjan 3
Acate 2
Alcalá de Henares 2
Algiers 2
Almaty 2
Auckland 2
Augusta 2
Banja Luka 2
Bantry 2
Cagliari 2
Chisinau 2
Groningen 2
Guangzhou 2
Ho Chi Minh City 2
Hull 2
Jinan 2
Totale 7.893
Salva come PNG Salva come JPEG
Nome #
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications 165
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 83
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis 78
Adalimumab in ulcerative colitis: hypes and hopes 72
Risk of postoperative recurrence and postoperative management of Crohn's disease 67
New Drug Delivery Systems in Inflammatory Bowel Disease: MMX (TM) and Tailored Delivery to the Gut 67
A Prospective Comparison Between Computerized Tomography (CT) and Magnetic Resonance (MR) in Ileo-Colonic Crohn's Disease: A Single-Center Experience. 65
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients 64
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study 62
Adalimumab is effective in achieving clinical and endoscopic long-term deep remission : a case report 59
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? 59
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes 58
JAK inhibitors: Novel developments in management of ulcerative colitis 58
Perception of reproductive health in women with inflammatory bowel disease 58
Accuracy of a New Fujiifilm Blue Light Prototype in Predicting the Histology of Subcentimetric Polyps 58
Impact of Tumour Necrosis Factor Antagonists on Avoiding Surgery in Stricturing Crohn's Disease: A Tertiary Center Real-Life Experience 57
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies 57
Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects? 57
Regulatory T-Cell Therapy for Crohn's Disease: In Vivo Veritas 56
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy 56
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease 56
Emerging biologics in the treatment of inflammatory bowel disease : what is around the corner? 55
Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? 55
Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome 55
Impact of Medications on Radiologic Disease Activity and Bowel Damage in Crohn's Disease: A Prospective Longitudinal MRI Study 55
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials 55
Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. 54
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease A Systematic Review and Meta-Analysis of Randomized Controlled Trials 53
Adalimumab in Crohn's disease : tips and tricks after 5 years of clinical experience 53
Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply 52
Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond? 52
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 52
The bacterial sensor Triggering Receptor Expressed on Myeloid cells 2 (TREM-2) is a crucial pathogenic mediator in inflammatory bowel disease (IBD) 52
Emerging therapeutic targets and strategies in Crohn's disease 51
Commentary: adjunct antibiotic combination therapy for ulcerative colitis - is it time to investigate Fusobacterium varium? 51
Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile 51
Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease 51
Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation 51
Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside 51
Balanced Propofol Sedation (BPS) Administered by Non-Anesthesiologists vs Midazolam Alone for Endoscopic Procedure in Patients With IBD: A Single Center Open-Label Trial 51
A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis 51
Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease : a case-matched analysis 51
Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target 51
Effect of Immunosuppression on Immune Response to Pneumococcal Vaccine in Inflammatory Bowel Disease: A Prospective Study 50
A PROLONGED FOLLOW-UP ON THE EFFICACY AND SAFETY OF INFLIXIMAB BIOSIMILAR CT-P13 IN IBD ACROSS ITALY: THE PROSIT COHORT 50
Are Surgical Rates Decreasing in the Biological Era In IBD? 50
A Prospective Comparison Between 1.5t Magnetic Resonance and 3t Magnetic Resonance in Ileo-Colonic Crohn's Disease: A Single Center Experience 49
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? 48
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target 48
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study 48
A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis 48
Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease 48
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 47
Adalimumab for the treatment of pediatric Crohn's disease 47
Familial aggregation in inflammatory bowel disease: Is it genes or environment? 47
A HEALTH TECHNOLOGY-RELATED COST DESCRIPTION CONCERNING ITALIAN IBD CENTRES DEALING WITH CROHN'S DISEASE: RESULTS FROM SOLE STUDY 47
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan 47
Effect of tumour necrosis factor antagonists on avoiding surgery in stricturing Crohn's disease: a tertiary centre real-life experience 46
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 45
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy 44
Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis 44
Clinical utility of the Lemann index and Rutgeerts score to predict postoperative course of Crohn's disease: a retrospective single-center cohort study. 44
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? 44
Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation 44
OP018 High-fat diet and inflammation drive intestinal fibrosis enhancing epithelial–mesenchymal transition through the activation of S1P3 signalling 44
Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease 44
MFSD2A Promotes Endothelial Generation of Inflammation-resolving Lipid Mediators and Reduces Colitis in Mice 44
IOIBD technical review on endoscopic indices for Crohn's disease clinical trials 43
Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target 43
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 43
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease 43
Novel therapeutic targets for inflammatory bowel disease 43
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update 43
Prospective observational study on inflammatory bowel disease patients treated with infliximab biosimilars: preliminary results of the PROSIT-BIO cohort of the IG-IBD 43
Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough? 42
Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis 42
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy 42
Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases 42
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease : a prospective study 42
Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group 42
MRI in Crohn's disease : current and future clinical applications 41
Dose Optimization Is Effective in Patients With Ulcerative Colitis Losing Response to Infliximab: A Collaborative Multicentre Retrospective Study 41
Early intervention in Crohn's disease: towards disease modification trials 41
Commentary: antibodies reacting with the infliximab Fab portion - something new? 41
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease 41
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease 41
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission 41
Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease 41
Contrast-enhancement at magnetic resonance enterography does not differentiate between fibrosis and inflammation in Crohn's disease: a prospective cohort study 40
Infliximab in Steroid-Dependent Ulcerative Colitis: Efficacy and Predictors of Clinical and Endoscopic Remission 40
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 40
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease 40
VAGUS NERVE STIMULATION REDUCES DISEASE ACTIVITY AND MODULATES SERUM AND AUTONOMIC BIOMARKERS IN BIOLOGICREFRACTORY CROHN'S DISEASE 40
‘Quality of care’ standards in inflammatory bowel disease: A systematic review 40
A PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY ASSESSING THE EFFECTIVENESS OF BUDESONIDE MMX® FOR MILD-TO-MODERATE ULCERATIVE COLITIS 40
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis 40
Clinical Utility of the LeMann Index and Rutgeerts Score to Predict Postoperative Course of Crohn's Disease: A Retrospective Single-Center Cohort Study 40
Cross-Sectional Imaging Modalities in Crohn's Disease 39
Integrins and adhesion molecules as targets to treat inflammatory bowel disease 39
Preventing Collateral Damage in Crohn's Disease: The L,mann Index 39
Totale 5.040
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.660
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.660
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020112 0 0 0 0 0 0 0 0 0 0 0 112
2020/20212.874 11 28 19 25 21 898 381 197 614 337 15 328
2021/20221.516 99 15 65 306 12 8 64 197 152 203 312 83
2022/20233.347 617 152 389 351 205 283 16 255 541 325 169 44
2023/20241.941 201 152 384 93 56 257 103 118 34 42 169 332
2024/2025222 61 61 25 57 18 0 0 0 0 0 0 0
Totale 10.012